Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04170920 · ClinicalTrials.gov registry record · NA

Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs

A NA study, sponsored by Indiana University.

Completed
Registry status
NA
Development phase
62
Enrollment target

NCT04170920: Completed NA study, sponsored by Indiana University.

NCT04170920 is a NA study that has completed, run by Indiana University. The registered enrollment target is 62 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04170920, a NA study, has completed, sponsored by Indiana University.

COMPLETED
Registry status
NA
Development phase
62 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the feasibility of an mobile-health strategy to improve patient-reported symptoms, promote life-saving medication adherence, and encourage healthy lifestyle behaviors in early stage breast cancer survivors receiving adjuvant Aromatase inhibitors, while beginning to predict psycho-social and demographic characteristics of those who benefit most from this approach. This will provide preliminary experience and evidence for larger, randomized clinical trials evaluating this methodology, which will have immediate and scalable influence on cancer survivor ship.

Primary Outcome

Feasibility will be measured by participants who use the application 5 or more days per week

Interventions

  • DEVICE LifeExtend-AI

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2020-02-17
Est. Completion 2022-08-09
Phase NA
Indiana University

890 total trials

What the finished NCT04170920 record still lists

NCT04170920 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 1 intervention - of which LifeExtend-AI is the first listed.

NCT04170920 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04170920 about?

NCT04170920 is a clinical study titled "Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs". The purpose of this study is to evaluate the feasibility of an mobile-health strategy to improve patient-reported symptoms, promote life-saving medication adherence, and encourage healthy lifestyle behaviors in early stage breast cancer survivors receiving adjuvant Aromatase inhibitors, while beginn...

What is the current status of trial NCT04170920?

This trial is currently completed. It is a NA study. The enrollment target is 62 participants. The study started on 2020-02-17. Estimated completion is 2022-08-09.

What interventions are being tested in trial NCT04170920?

The interventions under investigation include: LifeExtend-AI (DEVICE).

Who is sponsoring clinical trial NCT04170920?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04170920's enrollment target sits among peer trials

62 1157th of 2000 higher than 837 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03231150 · 62 participants · NA

    Plantar Fasciitis Randomized Clinical Control Trial

  • NCT03458676 · 62 participants · NA

    Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

  • NCT03596086 · 62 participants · Phase 1

    HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

  • NCT03603405 · 62 participants · Phase 1

    HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04170920, the US trial registry maintained by the National Library of Medicine. NCT04170920 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.